

# Qura Therapeutics

**Andrew Spaltenstein**

VP HIV Drug Discovery, GlaxoSmithKline





# QURA THERAPEUTICS


ANDREW SPALTENSTEIN,  
VP HIV DRUG DISCOVERY, GLAXOSMITHKLINE



# Qura Therapeutics: the concept

- Qura Therapeutics is a new joint academic/industry partnership dedicated to finding a cure for HIV/AIDS, and created to:
  - pool the best expertise of industry (product focus, discovery and development expertise) and academia (basic research, translational medicine, access to patient cohorts)
  - ensure a long term commitment to “critical scientific mass”, base-level funding, and pipeline access
- Qura Therapeutics is owned in equal parts by its shareholders (founding shareholders are: GlaxoSmithKline and University of North Carolina)
- Qura Therapeutics was announced May 11, 2015. Laboratory operations expected to commence in September 2015
- Cure Center Scientific approach: currently under review

# Qura Therapeutics





# Qura Therapeutics at start-up

## **GlaxoSmithKline contributes:**

- **seed funding**
- **drug discovery scientists, and drug discovery expertise (including potential access to discovery/development platforms)**
- **tool compounds, projects, pipeline assets (including potential licenses for HIV Cure Indication)**

## **University of North Carolina at Chapel Hill contributes:**

- **lab facilities and infrastructure (target size: up to 50 lab based FTE)**
  - **translational medicine expertise and infrastructure**
  - **cure assay platforms and projects**
- 